Preeclampsia Clinical Trial
Official title:
Analyses of Maternal Plasma Cadmium, Lead and Vanadium Levels in the Diagnosis and Severity of Late-onset Preeclampsia; A Prospective and Comparative Study From Turkey
Introduction: Cadmium, lead and vanadium important pollutants produced from anthropogenic
activities, has been suggested to be embryotoxic and fetotoxic in a lot of studies. However,
the causes of preeclampsia are little known and heavy metals merit further investigation. We
tested whether late-onset preeclampsia (L-PrE) was associated with exposure to these metals.
Methods: This study was designed to determine maternal plasma cadmium, lead and vanadium
concentrations in women with L-PrE (n=46) compared to those of normotensive women (n=46).
These three heavy metals concentrations measured using inductively coupled plasma-mass
spectrometry were compared.
This observational case-control study was conducted at the Department of Obstetrics and
Gynecology, Cengiz Gokcek Public Hospital, Gaziantep, Turkey, between March 2018 and June
2019. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep
University (reference no: 2019/36). The study strictly adhered to the principles of the
Declaration of Helsinki. All subjects included in the study gave oral and written informed
consent. Ninety-two women were enrolled in the study in two groups.
Data collection and Study intervention:
The diagnosis of L-PrE, as defined by the Committee on Terminology of the American College of
Obstetricians and Gynecologists (ACOG), is established based on the presence of proteinuria
(urinary excretion of protein ≥300 mg in a 24-h urine specimen, or proteinüria ≥1+ in
dipstick) and a blood pressure level of ≥90/140 mmHg (two blood pressure measurements 6 h
apart) that occurs after 34 weeks of gestation in a previously normotensive woman. The
diastolic and/or systolic blood pressure <110/160 mm Hg, it was accepted as mild; and in case
these values exceeded this level, it was accepted as severe. Every women in the study
population underwent obstetric ultrasound examination and fetal-maternal assesment was
carried out by one of the authors. The obstetric anamnesis were obtained from all subjects.
The dempograhic data like age, gravidity, parity, body mass index (BMI) and gestational age
were recorded. The gestational age was determined by calculation from the last menstrual
period and supported by the ultrasonography measurements at first trimester of gestation.
Maternal venous plasma samples were taken for measurement of cadmium, lead and vanadium
levels after the diagnosis of L-PrE in outpatient clinic. These samples quickly centrifuged
at 1,500 g for 10 min, plasma samples were seperated and stored at -80 C until the day of
measurement. All patients with L-PrE were also hospitalized and their pregnancies were
terminated. The samples of the control groups were obtained during the routine obstetrical
care examination in the third trimester of pregnancy. Then, these pregnant women were
followed-up until the delivery. Both groups were compared in terms of maternal age, BMI, week
of gestation, gravida, parity, live born, systolic/diastolic blood pressure, total protein in
spot urine sample, hemoglobin, hematocrit, platelet count, white blood cell count, urea, uric
acid, albümin, blood urea nitrogen, creatinine, liver function tests (AST, ALT), lactic acid
dehydrogenase, cadmium, lead and vanadium concentrions and infant weight at delivery. Small
for gestational age (SGA) neonate was defined as birth weight <10th percentile for
gestational age with Turkey's national nomogram as the reference for fetal growth. The
samples were transferred within boxes in ice molds to Yozgat Bozok University Science and
Technology Application and Research Center (Occupational and Environmental Toxicology
Laboratory) for measuring heavy metal and trace element levels. The frequency of seafood
consumption was divided into four categories: 2-3 per week, 1-2 per week, 1-2 per month, and
rare. Smoking was classified into 3 groups (none, formerly smoker, and active smoking).
Passive smoking was also categorized into 2 groups (no and yes). The education levels was
classified into 4 groups (illiterate, primary education, high school, and university). The
residences of women was classified as rural and urban. Furthermore, the residences of women
have divided either living near a busy street (around 100 metres) or not.Small for
gestational age (SGA) neonate was defined as birth weight <10th percentile for gestational
age with Turkey's national nomogram as the reference for fetal growth.
The method developed by Aliyev et al. was used for preparing the samples for analysis One
milliliter of plasma samples was placed into high-temperature-resistant Teflon tubes in a
microwave oven, and 5 mL Suprapur® (Merck, Darmstadt, Germany) nitric acid (HNO3) and 5 mL
ultra-pure water was added. All plasma samples were digested using a microwave digestion
system (Start D; Milestone, MD, USA). After digestion, each sample was made to a total volume
of 20 mL with 9 mL ultra-pure water in a 50 mL polypropylene tube. Nitric acid (Suprapur®,
65%) was used for digestion of samples and standard reference material. Ultra-pure water
(Direct-Q®; Millipore, Darmstadt, Germany) was used for dilution of the standard
(multi-element standard Chem-Lab, Zedelgem, Belgium) and sample preparations.
The three metals (cadmium, lead and vanadium) were measured using inductively coupled
plasma-mass spectrometry (Thermo Scientific ICAPQc, USA). The operating parameters were set
as follows: radiofrequency power 1550 W, nebulizer gas 0.96 L/min, plasma gas 0.88 L/min,
nebulizer pressure 3.01 bar, dwell time 0.01 milliseconds, and spray chamber temperature
3.7°C. The sampler probe was washed between injections by rinsing with ultrapure water for 30
s, followed by washing with 2% HNO3 for 45 s, and finally rinsing with ultrapure water for 45
s. After the washing steps, the instrument automatically ran the next sample. An 11-point
calibration curve (0.5-500 µg/L) was used to measure the level of each element. The r2 values
of the calibration curves of all metals were calculated, and the minimum value was 0.9994. To
ensure the accuracy of the results, each measurement of the samples and standards was
repeated three times. The results of these measurements showed that the relative standard
deviation (RSD) did not exceed 5%. Certified Reference Material (CRM-Seronorm™ Trace Elements
Whole Blood L-2, Sero AS, Billingstad, Norway) was used for the validation method. To check
the stability and sensitivity of the instrument, a mixture of internal standards (Hf) was
used, and the mean and RSD values of metals were also calculated. The variations of each
measurement of the quality controls was <15%. The relative percentage differences in
replicate analyses were <5% in the samples and standards.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |